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ABSTRACT 
 
Advances and success in cloning and genetic 
engineering may mean passenger pigeons, dodos, gastric-
brooding frogs, thylacines, woolly mammoths, and other 
extinct species will once again grace this planet. As de-
extinction becomes a reality, it is uncertain whether these 
animals are patent eligible. Diamond v. Chakrabarty 
opened the door to cloning multicellular organisms. Since 
then, the U.S. Patent Office’s Board of Patent Appeals and 
Interferences has found “non-naturally occurring, man-
made organisms including animals” to be patentable 
subject matter under 35 U.S.C. § 101. Because the initial 
case challenging this decision failed on procedural 
grounds, the underlying legal issue has not been addressed 
in a federal court. Congress forbids patents directed at, or 
encompassing, human organisms, but has been silent with 
respect to animals. The Supreme Court holds that sections 
of naturally occurring DNA are not patent eligible, while 
non-naturally occurring synthetic strands are. But the 
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Court has not considered organisms created from both 
naturally occurring and synthetic DNA, as would be the 
case in de-extinction. The Federal Circuit upheld a 
decision denying a patent for Dolly the cloned sheep, yet 
left room for successful patents of other cloned animals. 
The Federal Circuit’s distinction may lie between patenting 
the clone of an animal that already exists and patenting an 
animal that does not or no longer exists. In light of ever-
changing science and technology, there are few clear 
boundaries of what organisms can or cannot be patented. 
Practitioners need to be aware of the boundaries and the 
gray areas in the existing law to navigate a path towards 
patentability of de-extinct species. 
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INTRODUCTION 
 
The ability to successfully reintroduce a previously extinct 
animal is no longer confined to the pages of Jurassic Park.1 The de-
extinction movement is beginning to bring species back from 
extinction, through cloning and genetic engineering. In 1996, 
scientists successfully cloned a complex mammal, Dolly the 
sheep.2 Seven years later, Spanish and French scientists harvested 
DNA from the recently extinct Pyrenean ibex (the Spanish 
burcardo) and became the first scientists to clone an extinct 
animal.3 Earlier this year, geneticists inserted the DNA of a woolly 
mammoth into lab-grown elephant cells.4 
The motivation behind de-extinction is both pragmatic and 
fanciful. Supporters of de-extinction argue that species 
reintroduction carries the potential of medical and pharmaceutical 
discoveries.5 De-extinction allows for preservation and re-
establishment of ecosystems in danger of or already lost to 
extinction.6 Humanity is remorseful over the species that have been 
lost. There is a powerful and compelling desire to see animals that 
only exist in museums and the pages of books, alive and returned 
to the wild. 
Skeptics point to the instability of reintroducing an animal 
species into an environment no longer hospitable to its survival.7 
They caution that bringing back species may decrease the urgency 
                                                                                                             
1 MICHAEL CRICHTON, JURASSIC PARK (1990). 
2 ROSLIN INST., U. EDINBURGH, Dolly the Sheep: A Life of Dolly, 
http://www.roslin.ed.ac.uk/public-interest/dolly-the-sheep/a-life-of-dolly/ (last 
updated Apr. 7, 2015). 
3 Carl Zimmer, Bringing Them Back to Life, NAT’L GEO. (Apr. 2013), 
available at http://ngm.nationalgeographic.com/2013/04/125-species-revival/ 
zimmer-text. 
4 Tanya Lewis, Woolly Mammoth DNA Inserted into Elephant Cells, LIVE 
SCI. (Mar. 26, 2015, 5:42 PM), http://www.livescience.com/50275-bringing-
back-woolly-mammoth-dna.html. 
5 Zimmer, supra note 3. 
6 Id. 
7 Stuart Pimm, Opinion: The Case Against Species Revival, NAT’L 
GEOGRAPHIC NEWS (Mar. 12, 2013), http://news.nationalgeographic.com/ 
news/2013/03/130312--deextinction-conservation-animals-science-extinction-
biodiversity-habitat-environment. 
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of protecting fragile ecosystems, and warn about unintended 
consequences of interfering with established ecosystems. 
The methods used for de-extinction are patent eligible, but 
patent eligibility for the re-created animals themselves is uncertain. 
This Article examines the potential for obtaining patents on extinct 
animals that have been re-created through cloning and genetic 
engineering. First, it explores the evolution of patent protection for 
living organisms. Next, it explores the scientific techniques 
currently being used to bring extinct species back into existence. 
Finally, it discusses the probability and potential hurdles to 
obtaining a patent on a re-created animal. Ultimately, successful 
applications for patents on these animals must first demonstrate 
that the resulting animal has characteristics (structural, functional, 
or otherwise) that are different from its extinct predecessor. 
 
I. LIVING ORGANISMS AND 35 U.S.C. § 101 
 
A.  Non-Naturally Occurring Plants Are Patent Eligible Material 
 
Title 35, Section 101 of the U.S. Code defines patentable 
inventions as “any new and useful process, machine, manufacture, 
or composition of matter, or any new and useful improvement 
thereof . . . .”8 The Plant Patent Act of 1930 establishes that living 
organisms are not precluded from patent eligibility.9 The Act 
specifies that “[w]hoever invents or discovers and asexually 
reproduces any distinct and new variety of plant” can obtain a 
patent on it.10 In passing the legislation, Congress explained that 
the work of “the plant breeder ‘in aid of nature’ was patentable 
invention.”11 But in 1948, the United States Supreme Court held 
that naturally occurring, living organisms are not patentable, 
regardless of whether they are selected or mixed in a way not 
found in nature.12 In Funk Bros., a manufacturer sought a patent 
                                                                                                             
8 35 U.S.C. § 101 (2006). 
9 35 U.S.C. § 161 (2006). 
10 Id. 
11 Id. at 312 (quoting S. REP. NO. 315, at 6–8 (1930) (Conf. Rep.); H.R. REP. 
NO. 1129, at 7–9 (1930) (Conf. Rep.)). 
12 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948). 
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for a mixture of strains of bacteria that helped certain plants extract 
nitrogen from the air and fix it into the soil.13 The Court held that 
the mixture was not eligible for a patent because the bacteria used 
in it was scientifically unaltered and found in nature.14 Congress 
later sanctioned patent protection for certain sexually reproduced 
plants with the 1970 Plant Variety Protection Act.15 
 
B.  The Supreme Court Expands the Scope of Patent Eligible 
Organisms 
 
Diamond v. Chakrabarty challenged the United States Patent 
and Trademark Office’s (“USPTO”) denial of certain bacteria 
patent claims. The USPTO reasoned that bacteria were precluded 
from patent eligible material under § 101 because (1) 
microorganisms are “products of nature” and (2) living things are 
not patent eligible.16 The Supreme Court rejected this reasoning, 
concluding that the statutory category of “composition of matter” 
includes living organisms and is not limited by the Plant Protection 
and Plant Variety Protection Acts.17 Furthermore, the Court held 
that science and technology are not precluded patent protection 
simply because such methods were not conceptualized when §101 
was enacted.18 
Shortly after the Chakrabarty ruling, the USPTO issued two 
rulings through its Board of Patent Appeals and Interferences 
(“B.P.A.I.”), expanding the definition of patentable subject 
material. In the first, Ex parte Hibberd, the B.P.A.I. held that entire 
plants and tissue cultures are patentable subject material.19 A few 
years later in Ex parte Allen, the B.P.A.I. established that non-
naturally occurring animals are patent eligible.20 
                                                                                                             
13 Id. 
14 Id. (“[P]atents cannot issue for the discovery of the phenomena of 
nature.”). 
15 Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980). 
16 Id. at 306. 
17 Id. at 311. 
18 Id. at 318. 
19 Ex Parte Hibberd, 227 U.S.P.Q 443, 1985 WL 71986 (B.P.A.I. Sept. 24, 
1985). 
20 Ex Parte Allen, No. 86-1790, 1987 WL 123816 (B.P.A.I. Apr. 3, 1987), 
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The USPTO followed these rulings with a notice reiterating 
that “[t]he Patent and Trademark Office now considers non-
naturally occurring, nonhuman, multicellular, living organisms, 
including animals, to be patentable subject matter.”21 The USPTO 
placed a moratorium on granting subsequent patents on animals to 
give Congress time to debate the issues involved, weigh concerns 
from the public, and prescribe changes to the laws.22 No such 
hearings occurred. 
Eight months later, the USPTO lifted the moratorium and 
issued the first patent for a genetically modified animal: “the 
Harvard mouse.”23 The Harvard mouse triggered public concern 
and outrage.24 The controversy over this patent led animal rights 
organizations and concerned farmers to challenge the USPTO’s 
interpretation of the patent statute.25 Legal action was initiated, but 
the case was dismissed on standing grounds.26 To date, the 
Supreme Court has not addressed the substantive question of 
whether transgenic animals should be patentable. 
 
C.  The Boundaries of Obtaining Patents on Living Organisms 
 
1. Products of Nature Are Not Patent Eligible Subject Matter 
 
The scope of patentable subject matter in the United States is 
not without limits. Laws of nature, principles, physical phenomena, 
abstract ideas, and products of nature are not patent eligible.27 In 
particular, the Product of Nature doctrine prevents things already 
existing in nature from being patentable subject matter. However, 
it is not clear what falls within the scope of being a “product of 
                                                                                                             
aff’d, 846 F.2d 77 (Fed. Cir. 1988). 
21 Animals – Patentability, 1077 Off. Gaz. Pat. & Trademark Office 24 
(Apr. 21, 1987). 
22 36 PAT. TRADEMARK & COPYRIGHT J. (BNA) No. 888, at 271–72 (1988). 
23 U.S. Patent No. 4,736,866 (filed June 22, 1984) (issued Apr. 12, 1988). 
24 Elizabeth Hecht, Note, Beyond Animal Legal Defense Fund v. Quigg: The 
Controversy Over Transgenic Animal Patents Continues, 41 AM. U. L. REV. 
1023, 1041-44 (1992). 
25 Animal Legal Def. Fund v. Quigg, 932 F.2d 920 (Fed. Cir. 1990). 
26 Id. 
27 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
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nature.” In the wake of Chakrabarty, courts apply the doctrine as 
an inquiry into whether a naturally occurring product has been 
changed or altered to the extent that the claimed form does not 
exist in nature.28 This effectively limits what is a non-patent 
eligible, “product of nature.” The Supreme Court emphasizes that 
“the relevant distinction [is] not between living and inanimate 
things, but between products of nature, whether living or not, and 
human-made inventions.”29 A composition of matter that occurs in 
nature will be considered patentable if given a new form, quality, 
properties, or combination not present in the original article.30 
Anything can be deemed “made by man” so long as it does not 
occur naturally without the interference of man. In Funk Bros. and 
Chakrabarty, the Supreme Court offers examples of what is and 
what is not a product of nature, but the distinction is murky and not 
easily defined.31 
After Chakrabarty, the Product of Nature doctrine does not 
present a significant hurdle to patent eligibility in the USPTO or 
the courts. The USPTO began granting patents on naturally 
occurring DNA sequences that were “isolated” or “purified,” 
arguing that excised genes do “not occur in that isolated form in 
nature” and the “purified state is different from the naturally 
occurring compound.”32 In 2013, the USPTO’s stance was 
challenged in Ass’n for Molecular Pathology v. Myriad Genetics, 
Inc. Relying on the Product of Nature doctrine, the Supreme Court 
held that naturally occurring, isolated DNA segments are not 
                                                                                                             
28 Jerzy Koopman, The Patentability of Transgenic Animals in the United 
States of America and the European Union: A Proposal for Harmonization, 13 
FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 103, 123 n.79 (2002) (quoting E.S. 
VAN DE GRAAF, PATENT LAW AND MODERN BIOTECHNOLOGY: A COMPARATIVE 
STUDY ABOUT THE REQUIREMENTS AND THE SCOPE OF PROTECTION 28 (1997)).  
29 J.E.M. Ag Supply, Inc. v. Pioneer HI-Bred Int’l., Inc., 534 U.S. 124, 134 
(2001) (quoting Diamond v. Chakrabarty, 447 U.S. 303, 311–12 (1980)). 
30 Chakrabarty, 447 U.S. at 308. 
31 See, e.g., Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 
(1948) (finding that mixing together pre-existing bacteria in a manner that is not 
found in nature is still a product of nature); Diamond v. Chakrabarty, 447 U.S. 
303 (1980) (finding that inserting DNA into bacteria to produce an organism 
that is not found in nature is not product of nature). 
32 Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093, I(2) (Jan. 5, 
2001). 
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patent eligible although, non-naturally occurring synthetic 
segments of DNA are.33 
 
2. Cloned Organisms Are Generally Not Patentable Subject 
Matter 
 
In general, cloned animals are not patent eligible. The Federal 
Circuit Court of Appeals upheld the USPTO’s denial of a patent 
application for the first cloned mammal, Dolly the sheep.34 The 
court based its ruling on the fact that Dolly is an exact genetic 
replica of an existing animal; therefore, her “genetic identity to her 
donor parent renders her unpatentable.”35 Despite the ruling, the 
decision leaves potential for obtaining patents on cloned animals. 
The court specifies that “having the same nuclear DNA as the 
donor mammal may not necessarily result in patent ineligibility in 
every case,” emphasizing that at a minimum the clone must have 
“markedly different characteristics from the donor" of which it is a 
copy.36 
Success in genetic engineering and advances in cloning have 
opened the possibility of bringing species of animals back from 
extinction, raising questions about whether these animals will be 
patent eligible under existing patent law. These re-created animals 
previously existed in nature but as a result of human behavior, or 
other events, are now extinct and no longer exist in nature. Their 
re-creation is entirely dependent upon the intervention of man with 
the ultimate goal of creating a genetic match to the original 
species. The process fails to fall neatly within the Product of 
Nature doctrine, pushing at its already tenuous boundaries. 
  
  
                                                                                                             
33 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 
2115–20 (2013).  
34 In re Roslin Inst., 750 F.3d 1333 (Fed. Cir. 2014). 
35 Id. at 1337. 
36 Id. at 1339. 
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II. THE SCIENCE OF DE-EXTINCTION 
 
A.  Cloning As a Tool For De-Extinction 
 
De-extinction through cloning begins with the removal of DNA 
from the preserved tissue specimen of an animal. The original 
DNA must be intact and without any deterioration.37 The DNA is 
placed into the nucleus of a reproductive egg from another animal 
that has been cleared of its own genetic material.38 The cell is 
manipulated to begin dividing and eventually the embryo is placed 
into a surrogate mother of a compatible species.39 The resulting 
animal is the genetic twin of the donor animal. 
Part of the difficulty of cloning extinct animals is the fact that 
DNA typically undergoes some level of decay, depending on how 
long the species has been extinct. Animals recently extinct or at-
risk of extinction are the best candidates for cloning. The DNA 
used with the Pyrenean ibex clone in Spain was obtained from the 
last living ibex, Celia, shortly after she died.40 Nonetheless, the 
fragility of DNA limits the broad application of cloning as a means 
for de-extinction. 
 
B.  Genetic Engineering of Extinct Species 
  
Genetic engineering techniques address the problems of DNA 
decay in extinct animals. Scientists compare the mapped DNA 
obtained from extinct animals with the DNA of similar, non-
extinct animals to identify key mutations that differentiate the two 
species.41 Germ cells are stimulated from the similar or compatible 
species.42 Strands of DNA matching the extinct animal are 
                                                                                                             
37 Brian Switek, How to Resurrect Lost Species, NAT’L GEOGRAPHIC 
NEWS (Mar. 11, 2013), http://news.nationalgeographic.com/news/2013/13/ 
130310-extinct-species-cloning-deextinction-genetics-science. 
38 Id. 
39 Id. 
40 Zimmer, supra note 3. 
41 Id. 
42 Nathaniel Rich, The Mammoth Cometh, N.Y. TIMES MAG. (Feb. 27, 
2014), http://www.nytimes.com/2014/03/02/magazine/the-mammoth-
cometh.html?_r=1. 
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synthetically created and then “cut and pasted” into the DNA in the 
germ cells of the similar species in order to make it function like 
the extinct animal’s DNA.43 These germ cells are placed into an 
embryo of the compatible species integrating into that animal’s 
reproductive organs.44 The embryo will grow normally, but it now 
carries eggs or sperm of the reconstructed extinct animal.45 
Breeding two of these “chimeras” will result in the birth of the 
once extinct animal.46 
Genetically restored extinct animals could be a reality by 2020 
and clones of recently extinct animals could exist sooner.47 
Although patent eligibility of de-extinct animals is uncertain, 
patent eligibility for the processes of de-extinction is not in 
question. Dolly is not patent eligible, but the Roslin Institute holds 
a patent on the method used to clone her.48 The question remains: 
can the genetic re-creation of an animal that previously existed in 
nature be patent eligible? 
 
III. THE PROBABILITY OF PATENT ELIGIBILITY 
 
An animal generated through the de-extinction process could 
be deemed patent eligible. The re-created animal will not be an 
exact genetic copy of an animal that already exists and will have 
different structural characteristics than the original species. 
Therefore, no precedent forbids it and the trend of patent law is 
permissive in this area. 
 
A.  The Arguments in Favor of Patent Eligibility 
 
Re-created extinct animals will have markedly different 
characteristics than the original animal, rendering them an 
exception to the Product of Nature doctrine and therefore, patent 
eligible. Patents are currently granted for transgenic animals 
                                                                                                             
43 Id. 
44 Id. 
45 Id.  
46 Id. 
47 Zimmer, supra note 3. 
48 In re Roslin Inst., 750 F.3d 1333 (Fed. Cir. 2014). 
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created for medical and scientific research.49 Furthermore, the 
Federal Circuit’s Dolly ruling left potential for obtaining a patent 
on a cloned animal.50 Minor differences of the extinct animal’s 
DNA or cellular structure are likely to be enough to demonstrate 
that the new animal is distinct from the parent organism. The 
fragile nature of extinct animal DNA allows for multiple avenues 
of differentiation from the original animal. 
Myriad’s ruling that non-naturally occurring synthetically 
produced strands of DNA are patentable supports the patent 
eligibility of extinct animals.51 Transgenic de-extinction processes 
depend on creating synthetic strands of DNA and splicing them 
together with naturally occurring DNA to replicate the DNA 
structure of the extinct animal. Although the goal is to replicate the 
extinct animal’s DNA, it will not create a naturally occurring 
genome. Indeed, the degradation of the original species’ DNA 
makes it impossible to determine how close or different the two 
genomes are. 
The fact that the resultant animal is a re-creation of an animal 
that no longer exists naturally further lends support to its patent 
eligibility. The state of being extinct may place the animal outside 
the category of a “product of nature.” An extinct animal’s species 
by definition does not exist in nature. As such, it is no longer 
naturally occurring. The re-created animal is fundamentally 
distinct because it cannot be compared to a current composition in 
nature. 
The hurdle for obtaining patents on an animal brought back 
through de-extinction is whether it will fall outside the Product of 
Nature doctrine. Re-created extinct animals will likely fall outside 
the Products of Nature doctrine because they are distinctly 
                                                                                                             
49 See, e.g., U.S. Patent No. 4,736,866 (filed June 22, 1984) (transgenic non-
human eukaryotic animal whose germ cells and somatic cells contain active 
oncogene sequence); U.S. Patent No. 5,574,206 (filed Aug. 24, 1994) 
(transgenic mouse used for HIV research); U.S. Patent No. 5,602,301 (filed 
Nov. 16, 1994) (animal with successful graft specific to myocardial tissue); U.S. 
Patent No. 7,550,649 (filed Oct. 28, 2004) (transgenic mouse used in 
Parkinson’s Disease research). 
50 In re Roslin Inst., 750 F.3d 1333 (Fed. Cir. 2014) 
51 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 
2115–2120 (2013). 
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different than a naturally occurring animal. For the above reasons, 
initial animals produced as a result of de-extinction processes will 
likely be deemed patent eligible subject matter under current U.S. 
patent law. 
 
B.  The Arguments Against Patent Eligibility 
 
Granting patents for animals has not been without controversy. 
Many groups are concerned about the potential ramifications of 
allowing animals to be patented as evidenced in the Animal Legal 
Defense Fund suit. Growing discontent in corporate ownership of 
plant patents has increased public skepticism of “owning” living 
organisms.52 Obtaining patents on animals intended for release into 
nature is likely to be met with more resistance and challenge. 
Despite the likelihood that de-extinct animals will be deemed 
patent eligible subject matter under existing law, the scope of such 
patent protection is unclear. Patents for the first generation of 
organisms may survive the Products of Nature doctrine, but what 
about their offspring? The patent eligibility for the offspring of two 
transgenic re-created animals could be ripe for controversy under 
the Products of Nature doctrine. Can a wild animal, born of natural 
sexual reproduction fall outside the definition of a “product of 
nature” simply because its progenitor was the result of genetic 
engineering?  
 
C.  The Novelty of Re-Creation 
 
Although transgenic animals may meet the criteria for 
patentable subject matter, there may be other barriers to obtaining 
                                                                                                             
52 See, e.g., Campaigns – Animal Patents, AMERICAN ANTI-VIVISECTION 
SOCIETY, http://aavs.org/our-work/campaigns/animal-patents (last visited Dec. 
20, 2015); About no patents on seeds, NO PATENTS ON SEEDS, https://no-
patents-on-seeds.org/en/about-us/about-no-patents-seeds (last visited Dec. 3, 
2015); and Andrew B. Perzigian, Detailed Discussion of Genetic Engineering 
and Animal Rights: The Legal Terrain and Ethical Underpinnings, ANIMAL 
LEGAL AND HISTORICAL CENTER, MICH. ST. UNIV. COLLEGE OF LAW (2003), 
available at https://www.animallaw.info/article/detailed-discussion-genetic-
engineering-and-animal-rights-legal-terrain-and-ethical (last visited Dec. 3, 
2015). 
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patent protection. Patent eligibility requires the invention be new, 
non-obvious, and useful in addition to being patentable subject 
matter.53 A patent cannot be obtained if “the claimed invention was 
. . . otherwise available to the public before the filing date of the 
claimed invention.”54 Additionally, a patent will be denied “if the 
differences between the claimed invention and the prior art are 
such that the claimed invention as a whole would have been 
obvious before the effective filing date of the claimed invention to 
a person having ordinary skill in the art to which the claimed 
invention pertains.”55 The core purpose of de-extinction is to bring 
back an animal that previously existed in nature. Many of the 
arguments justifying transgenic animals as patent eligible subject 
matter extend to defending that they are new and non-obvious, but 
a full discussion of this issue exceeds the scope of this Article. 
In many ways the movement to re-create previously extinct 
animals underscores the purpose of the patent system “[t]o 
promote the Progress of Science and useful Arts . . . .”56 Scientists 
and visionaries are actively collaborating to push the boundaries of 
science for the benefit of humanity. Patent protection creates 
further incentive to engage and invest in biotechnology. In 
exchange for the limited monopoly granted by a patent, the public 
is rewarded by the re-introduction of unique and beneficial species 
and the disclosure of how they were created.57 Despite these 
benefits, successful recreation of a previously extinct animal is 
likely to generate public debate and scrutiny. In the face of public 
pressure, Congress has the ability to draft legislation to explicitly 
allow or limit patent eligibility for animals. For example, in the 
2011 America Invents Act, Congress put limitations on 
patentability for human organisms.58 With enough pressure and 
                                                                                                             
53 See, e.g., 1-3 CHISUM ON PATENTS § 3.01 (2015); 1-4 CHISUM ON 
PATENTS § 4.01(2015); 1-5 CHISUM ON PATENTS § 5.01 (2015). 
54 35 U.S.C. § 102 (a)(1) (2000). 
55 35 U.S.C. § 103. 
56 U.S. CONST. art. I, § 8, cl. 8. 
57 JOHN G. SPRANKLING & RAYMOND R. COLETTA, PROPERTY: A 
CONTEMPORARY APPROACH (2nd ed. 2012). 
58 Leahy-Smith America Invents Act (AIA), Pub. L. 112-29, § 33(a), 125 
Stat. 284, 340 (2011) (“Notwithstanding any other provision of law, no patent 
may issue on a claim directed to or encompassing a human organism.”). 
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media attention it is possible that the ability to patent a pigeon or 
woolly mammoth will ultimately be decided on Capitol Hill. 
 
CONCLUSION 
 
 De-extinction offers the possibility of returning previously 
extinct animals to the planet, but the ability of scientist-creators to 
own the patent rights to these animals is uncertain. At this time, 
these organisms seem to fall within the scope of patent eligible 
subject material. With success brings publicity, and an application 
for a patent on the dodo, passenger pigeon, or woolly mammoth 
may result in controversy and possibly congressional limits. But 
absent congressional action, a carefully drafted application, 
mindful of the margins of the law, may result in a patent that can 
sustain subject matter challenge in the courts. 
  
PRACTICE POINTERS 
 
 To fall outside the Product of Nature doctrine, a patent 
application for a clone of a previously extinct animal needs 
to specify how the resulting animal is fundamentally 
different from the parent. 
 In the absence of congressional intervention, a transgenic 
animal that was previously extinct will likely be patent 
eligible so long as it remains genetically distinct from the 
original animal. 
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